ERS Genomics Announces Agreement With New England Biolabs to Commercialize CRISPR Gene Editing Tools and Reagents

ERS Genomics Limited, today announced it has signed an agreement with New England Biolabs (NEB®), a global leader in the discovery and production of enzymes for molecular biology applications, granting NEB rights to sell CRISPR/Cas9 tools and reagents.

Please to read the entire article.

You must be logged in to post a comment Login